Nektar Therapeutics (NKTR)

20.15
NASDAQ : Health Technology
Prev Close 20.22
Day Low/High 20.02 / 20.76
52 Wk Low/High 16.56 / 62.70
Avg Volume 2.65M
Exchange NASDAQ
Shares Outstanding 175.27M
Market Cap 3.54B
EPS 4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
Nektar Can't Shake Tempered Exubera

Nektar Can't Shake Tempered Exubera

Its stock will be linked to Exubera's poor launch, at least until some of its other drugs hit the market.

Nektar Slashes Staff

The company will fire 25% of its employees.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Biotech and pharmaceutical stocks were flat, even with Hologic's $6.2 billion deal for Cytyc.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

SuperGen is rising.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Forest Laboratories is weaker.

Nektar Names CEO

Howard W. Robin will take the post.

Expectations Deflated for Alkermes

Expectations Deflated for Alkermes

The company's alcohol-treatment drug did not have the expected impact.

Friday's Analysts' Upgrades and Downgrades

Friday's Analysts' Upgrades and Downgrades

Who made what calls.

Cramer's ' Mad Money' Lightning Round: Not Sipping the Nektar

Cramer's ' Mad Money' Lightning Round: Not Sipping the Nektar

Cramer admits to being wrong on the biopharmaceutical company.

Cramer's 'Mad Money' Recap: Playing Nice With NYSE

Cramer's 'Mad Money' Recap: Playing Nice With NYSE

Cramer says mea culpa about not being an NYSE fan and also gets a kick out of the Giants' Jay Feely.

Monday's Health Winners & Losers

Monday's Health Winners & Losers

Novogen is on the rise.

Friday's Analysts' Upgrades and Downgrades

Friday's Analysts' Upgrades and Downgrades

Who made what calls.

Cramer's 'Mad Money Lightning Round': Chipotle on Its Shoulder

Cramer's 'Mad Money Lightning Round': Chipotle on Its Shoulder

Cramer prefers McDonald's to the Mexican fast-food outfit.

Novo Nordisk Sues Pfizer

Novo Nordisk Sues Pfizer

The Danish company alleges patent infringement over Exubera.

Pfizer Postpones Exubera Launch

The inhaled insulin will go on sale in September, a few weeks later than planned.

Exubera Success May Hinge on Usability

Exubera Success May Hinge on Usability

Pfizer and Nektar will know soon enough if diabetics are ready to make the switch from injections to inhaled insulin.

Pfizer Seeks Pricing Perfection

Pfizer Seeks Pricing Perfection

The cost of the inhaled insulin Exubera hasn't been disclosed, but the drug hits the market in July.

Biotechs Find Riches in Orphaned Niches

Biotechs Find Riches in Orphaned Niches

A focus on neglected or rare disorders may help biotechs.

Pfizer Presses Case Against Shots

Pfizer Presses Case Against Shots

The drugmaker says two studies show that diabetics will prefer inhaled insulin to injections.

Pfizer Plans Mid-July Debut for Inhaled Insulin

Pfizer Plans Mid-July Debut for Inhaled Insulin

The drugmaker has yet to announce a price for the treatment, which it touts as more convenient than injectable insulin.

Diabetes Care's Turning Point

Diabetes Care's Turning Point

This year's ADA meeting is set to showcase new and upcoming treatment options.

RealMoney Radio Recap: Fear Factor

RealMoney Radio Recap: Fear Factor

Cramer says the market is causing a lot of investor fright.

RealMoney Radio: Bye-Bye, Akamai

RealMoney Radio: Bye-Bye, Akamai

Cramer says the opportunity to buy this stock has come and gone.

No Juice for Nektar

The insulin company posts a loss but its shares hold steady.

Cramer's 'Mad Money' Recap: West Pharma's Numbers in Safety

Cramer's 'Mad Money' Recap: West Pharma's Numbers in Safety

The drug safety stock just hit a 52-week high but could see another boost soon. Cramer explans why.

Cramer's 'Mad Money' Recap: Kinetic Diabetic Plays

Cramer's 'Mad Money' Recap: Kinetic Diabetic Plays

Cramer offers his take on Matria, Healthways, Amylin and Nektar Therapeutics in the diabetic sector. Plus, UnitedHealth's CEO gets grilled on options.

Cramer's 'Mad Money' Recap: Biotech Bundling

Cramer's 'Mad Money' Recap: Biotech Bundling

Alliances with big pharma are key for boosting smaller companies' profiles.

Loss Widens for Nektar

The company expects to lose $115 million to $130 million in 2006.

Today's Health Winners and Losers

Today's Health Winners and Losers

Misonix soars 57% after the FDA clears its product for removing soft tissue legions in surgeries.

FDA Approves Inhaled Insulin

FDA Approves Inhaled Insulin

Exubera has now been cleared in the U.S. and Europe.

TheStreet Quant Rating: D (Sell)